# NRSNW (NeuroSense Therapeutics Ltd.) - SEC EDGAR Financial Statements

> NeuroSense Therapeutics Ltd. reported $1.03M in total assets and a net loss of $11.12M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/NRSNW
- Markdown: https://convexityos.com/fundamentals/NRSNW.md
- SEC CIK: 0001875091
- Reporting currency: USD
- Latest filing period: December 31, 2025
- Last synced: Nov 21, 2026, 05:10 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001875091&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$11.09M | Operating profit |
| Net Income | FY 2025 | -$11.12M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.44 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$7.68M | Operating CF less CapEx |
| Cash & ST Investments | Dec 31, 2025 | $166K | Total debt: $170K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $6.23M | $5.70M | $7.27M | $5.59M | -- | -- | -- |
| **Operating Income** | -$11.09M | -$9.90M | -$12.05M | -$10.55M | -$5.59M | -$2.89M | -$1.24M |
| **EBITDA** | -$11.07M | -$9.88M | -$12.03M | -$10.54M | -$5.58M | -$2.88M | -- |
| Interest Income | -- | -- | $4.23M | $1.26M | $2.73M | $61K | $18K |
| Interest Expense | -- | -- | $2.21M | $45K | $1.19M | $1.0K | $5.0K |
| **Net Income** | -$11.12M | -$10.21M | -$10.11M | -$10.49M | -$4.04M | -$2.83M | -$1.22M |
| Basic EPS | -$0.44 | -$0.54 | -$0.74 | -$0.91 | -$0.65 | -$0.51 | -$0.26 |
| **Diluted EPS** | -$0.44 | -$0.54 | -$0.74 | -$0.91 | -$0.65 | -$0.51 | -- |
| Basic Shares Outstanding | 25.5M | 18.6M | 13.6M | 11.5M | -- | -- | -- |
| Diluted Shares Outstanding | 25.5M | 18.6M | 13.6M | 11.5M | -- | -- | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $166K | $3.38M | $2.64M | $3.54M | $11.06M | $699K |
| **Cash & Short-Term Investments** | $166K | $3.38M | $2.64M | $3.54M | $11.06M | $699K |
| Accounts Receivable, Net | -- | -- | $236K | $255K | $310K | $30K |
| **Total Current Assets** | $778K | $4.40M | $2.92M | $7.38M | $11.41M | $766K |
| Property, Plant & Equipment, Net | $58K | $66K | $85K | $77K | $19K | $13K |
| **Total Non-Current Assets** | $250K | $173K | $269K | $329K | $19K | $13K |
| **Total Assets** | $1.03M | $4.58M | $3.19M | $7.71M | $11.43M | $779K |
| Accounts Payable | $799K | $1.16M | $1.46M | $498K | $39K | $55K |
| Other Current Liabilities | $1.72M | $832K | $2.00M | -- | -- | -- |
| **Total Current Liabilities** | $2.52M | $1.99M | $3.46M | $1.73M | $597K | $120K |
| **Total Non-Current Liabilities** | $72K | $0 | $1.49M | $365K | $1.83M | $0 |
| **Total Liabilities** | $2.59M | $1.99M | $4.94M | $2.09M | $2.42M | $120K |
| **Total Debt (incl. Leases)** | $170K | $73K | $69K | $294K | -- | -- |
| Retained Earnings | -$47.78M | -$36.66M | -$26.12M | -$20.79M | -$8.45M | -$4.41M |
| **Total Stockholders' Equity** | -$1.56M | $2.58M | -$1.76M | $5.84M | $10.83M | $659K |
| Total Equity | -$1.56M | $2.58M | -$1.76M | $5.84M | $10.83M | $659K |

### Balance Sheet (Quarterly)

| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $166K | $3.38M | $2.64M | $3.54M | $11.06M | $699K |
| **Cash & Short-Term Investments** | $166K | $3.38M | $2.64M | $3.54M | $11.06M | $699K |
| Accounts Receivable, Net | -- | -- | $236K | $255K | $310K | $30K |
| **Total Current Assets** | $778K | $4.40M | $2.92M | $7.38M | $11.41M | $766K |
| Property, Plant & Equipment, Net | $58K | $66K | $85K | $77K | $19K | $13K |
| **Total Non-Current Assets** | $250K | $173K | $269K | $329K | $19K | $13K |
| **Total Assets** | $1.03M | $4.58M | $3.19M | $7.71M | $11.43M | $779K |
| Accounts Payable | $799K | $1.16M | $1.46M | $498K | $39K | $55K |
| Other Current Liabilities | $1.72M | $832K | $2.00M | -- | -- | -- |
| **Total Current Liabilities** | $2.52M | $1.99M | $3.46M | $1.73M | $597K | $120K |
| **Total Non-Current Liabilities** | $72K | $0 | $1.49M | $365K | $1.83M | $0 |
| **Total Liabilities** | $2.59M | $1.99M | $4.94M | $2.09M | $2.42M | $120K |
| **Total Debt (incl. Leases)** | $170K | $73K | $69K | $294K | -- | -- |
| Retained Earnings | -$47.78M | -$36.66M | -$26.12M | -$20.79M | -$8.45M | -$4.41M |
| **Total Stockholders' Equity** | -$1.56M | $2.58M | -$1.76M | $5.84M | $10.83M | $659K |
| Total Equity | -$1.56M | $2.58M | -$1.76M | $5.84M | $10.83M | $659K |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$11.12M | -$10.21M | -$10.11M | -$10.49M | -$4.04M | -$2.83M | -$1.22M |
| Depreciation & Amortization | $16K | $22K | $21K | $12K | $3.0K | $3.0K | -- |
| Stock-Based Compensation | $2.14M | $557K | $1.54M | $1.73M | $4.16M | $2.06M | $611K |
| Change in Payables | -$361K | -$299K | $961K | $459K | -$16K | $32K | $23K |
| **Operating Cash Flow** | -$7.67M | -$10.13M | -$8.35M | -$7.62M | -$1.54M | -$695K | -$582K |
| Capital Expenditure | -$8.0K | -$3.0K | -$29K | -$70K | -$17K | -$9.0K | -$7.0K |
| **Free Cash Flow** | -$7.68M | -$10.14M | -$8.38M | -$7.69M | -$1.56M | -$704K | -$589K |
| **Investing Cash Flow** | -$8.0K | $1.0K | $3.47M | -$3.59M | -$17K | -$9.0K | -$26K |
| Common Stock Issued | $7.0K | -- | $3.97M | -- | $9.86M | $508K | $1.42M |
| Dividends Paid | -- | -- | -$310K | -$310K | -$29K | -$28K | -$27K |
| **Financing Cash Flow** | $4.43M | $10.91M | $3.98M | $3.77M | $11.90M | $508K | $1.42M |
| **Net Change in Cash** | -- | -- | -$903K | -$7.52M | $10.36M | -$196K | $809K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -- | -395.3% | -- | -179.5% | -37.3% | -429.1% | -- |
| Return on Assets (ROA) | -1082.2% | -223.2% | -317.3% | -136.1% | -35.4% | -363.0% | -- |
| Current Ratio | 0.31x | 2.21x | 0.84x | 4.28x | 19.12x | 6.38x | -- |
| Quick Ratio | 0.07x | 1.70x | 0.83x | 2.20x | 19.05x | 6.08x | -- |
| Debt to Equity | -- | 0.03x | -- | 0.05x | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
